↓ Skip to main content

A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis

Overview of attention for article published in BMC Rheumatology, May 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
11 Mendeley